Global Markets for Bioengineered Protein Drugs

Published - Jan 2017| Analyst - Shalini Shahani Dewan| Code - BIO009G
Global Markets for Bioengineered Protein Drugs
Single User License: $2,750 Member Price: FREE

Report Highlights

The global market for bioengineered protein drugs is expected to reach $228.4 billion by 2021 from $172.5 billion in 2016, rising at a compound annual growth rate (CAGR) of 5.8% from 2016 through 2021.

Report Includes

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles major companies involved in the production and modification of protein drugs.

Report Scope

Bioengineered protein drugs are drugs that help treat chronic diseases like diabetes, asthma, cancer, various blood disorders, fertility disorders, immunological disorders and hormonal disorders. This report focuses on the global bioengineered protein drug market and its products, and provides an updated review of its applications in various arenas of biomedical research.

The scope of the study is global. BCC Research analyzes each market and its application, regulatory environment, technologies involved, new products and advancements, market projections and market shares. The technological issues include all the latest trends, pipeline products and developments.

The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, therapeutic enzymes, blood factors, and peptide hormones. These products are all bioengineered and produced by recombinant DNA technology.

The geographical regions covered in the report are North America, Europe, and emerging markets. The emerging market segment covers countries including India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead to the bioengineered protein drugs industry. Some of the major players of the market include Eli Lilly and Co., AbbVie Inc., F. Hoffmann–La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc., among others.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Aug-2014| Analyst - Shalini Shahani Dewan| Code - BIO009F

Report Highlights

The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.

Report Includes

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles of the major companies involved in the production and modification of protein drugs.
Published - Jan-2007| Analyst - Gargi Talukder| Code - BIO009E

Report Highlights

  • The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%.
  • Modified and engineered antibodies present the largest share of the total global market. In 2006, this sector held almost 56% of the global market. By the end of 2011 its share will drop slightly but not significantly to 54%.
  • Hormone protein drugs have the largest AAGR through the forecast period, averaging 5.1% through 2011 to reach $11.9 billion by 2011.

Published - Jan-2004| Analyst - Robert Cyran| Code - BIO009D

Report Highlights

  • In 2002, drug companies sold nearly $33 billion in protein drugs, and they are projected to approach $40 billion in 2003.
  • Rising at an average annual growth rate (AAGR) of 12.2%, this market is expected to reach $71 billion in 2008.
  • Replacement proteins constitute the bulk of the market and will rise at an AAGR of 9.8% from $31.4 billion in 2003 to $50 billion in 2008.
  • Monoclonal antibodies and fusion proteins will rise from $8.5 billion in 2003 to $20.1 billion in 2008.
  • These products effectively strip market share from older, less effective therapies. Most notably, a number of monoclonal antibodies are in the last stages of clinical trials for the treatment of autoimmune disease and cancer and promise to be blockbuster products.

Want to Customize this Report?

Contact us for a confidential discussion.

781-205-2433

Custom Report
RELATED REPORTS
Share This Report